Verapamil to protect insulin production in children with new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests if verapamil (a common blood pressure medication) can help children newly diagnosed with type 1 diabetes keep making their own insulin for longer. It aims to preserve the body's own insulin-producing cells, which may reduce the amount of insulin injections needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 4 and 9 years old when diagnosed with type 1 diabetes.
- Diagnosis must have happened within the last 3 months.
- Blood tests must show your child still makes some insulin (C-peptide level > 0.12 nmol/ml).
- Your child must have at least one diabetes-related antibody (such as GADA, IAA, IA-2A, or ZnT8A).
- Your child cannot have heart problems, low blood pressure, or a history of anemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study looks at children who have just started insulin for new-onset type 1 diabetes. It aims to test an intervention early in the course of the disease, which may help change how the immune system and diabetes progress.
This study tests the drug dimethyl fumarate (an oral medication already used for other conditions) to see if it can help people newly diagnosed with type 1 diabetes keep making their own insulin for longer. The goal is to slow down the immune attack on the pancreas.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
This study tests whether a special treatment aimed at gut bacteria can help children newly diagnosed with type 1 diabetes. It is for kids ages 6 to 12 who were diagnosed in the last 6 months and do not have other serious health conditions.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.